抄録
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 % of patients in the high DPD activity group but, in 70.6 % in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 3789-3792 |
| ページ数 | 4 |
| ジャーナル | Anticancer research |
| 巻 | 22 |
| 発行部数 | 6 B |
| 出版物ステータス | 出版済み - 11 1 2002 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
これを引用
Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. / Saeki, Hiroshi; Ito, Shuhei; Futatsugi, Motonori; Kimura, Yasue; Ohga, Takefumi; Sugimachi, Keizo.
：: Anticancer research, 巻 22, 番号 6 B, 01.11.2002, p. 3789-3792.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer
AU - Saeki, Hiroshi
AU - Ito, Shuhei
AU - Futatsugi, Motonori
AU - Kimura, Yasue
AU - Ohga, Takefumi
AU - Sugimachi, Keizo
PY - 2002/11/1
Y1 - 2002/11/1
N2 - Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 % of patients in the high DPD activity group but, in 70.6 % in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.
AB - Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 % of patients in the high DPD activity group but, in 70.6 % in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0036875153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036875153&partnerID=8YFLogxK
M3 - Article
C2 - 12552994
AN - SCOPUS:0036875153
VL - 22
SP - 3789
EP - 3792
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 6 B
ER -